MRI operation modes for implantable medical devices

Information

  • Patent Grant
  • 8543207
  • Patent Number
    8,543,207
  • Date Filed
    Friday, July 8, 2011
    12 years ago
  • Date Issued
    Tuesday, September 24, 2013
    10 years ago
Abstract
One embodiment of the present invention relates to an implantable medical device (“IMD”) that can be programmed from one operational mode to another operational mode when in the presence of electro-magnetic interference (“EMI”). In accordance with this particular embodiment, the IMD includes a communication interface for receiving communication signals from an external device, such as a command to switch the IMD from a first operation mode to a second operation mode. The IMD further includes a processor in electrical communication with the communication interface, which is operable to switch or reprogram the IMD from the first operation mode to the second operation mode upon receiving a command to do so. In addition, the IMD includes a timer operable to measure a time period from when the processor switches the IMD to the second operation mode. In accordance with this aspect of the invention, the processor is in electrical communication with the timer, and is further operable to switch the IMD from the second operation mode back to the first operation mode when the measured time period reaches a predetermined time period.
Description
BACKGROUND OF THE INVENTION

The present invention relates generally to implantable medical devices (“IMDs”), and more particularly to systems, devices and methods for rendering IMDs more safe in the presence of strong electro-magnetic interference, such as those produced by a magnetic resonance imaging (“MRI”) system.


IMDs can be used to provide a number of different medical therapies to patients. For example, therapeutic IMDs can include pacemakers, implantable cardioverter defibrillators (“ICDs”), blood pumps, drug delivery devices, neurostimulating devices, and the like. Some of the most common IMDs include pacemakers and ICDs (collectively referred to as cardiac rhythm management (“CRM”) devices), which are used to control the heart rate when heart rhythm disorders occur.


Magnetic resonance imaging (MRI) is an efficient technique used in the diagnosis of many disorders, including neurological and cardiac abnormalities and other diseases. MRI has achieved prominence in both the research and clinical arenas. It provides a non-invasive method for examining internal body structures and functions. Because MRI has become such a useful diagnostic tool, it now is used extensively in hospitals and clinics around the world.


As one skilled in the art will appreciate, MRI systems produce extensive electromagnetic fields during operation. In particular, MRI systems generally produce (and utilize) three types of electromagnetic fields: 1) a strong static magnetic field; 2) a time-varying gradient field; and 3) a radio frequency (RF) field which consists of RF pulses used to produce an image. The static field produced by most MRI systems has a magnetic induction ranging from about 0.5 to about 1.5 T. The frequency of the RF field used for imaging is related to the magnitude of the static magnetic field, and, for current-generation MRI systems, the frequency of the RF field ranges from about 6.4 to about 64 MHz. The time-varying gradient field is used in MRI for spatial encoding, and typically has a frequency in the Kilohertz range.


These strong electromagnetic fields produced by MRI systems can cause problems for implantable medical devices, such as CRM devices. For example, the static magnetic field can affect the magnetically controlled (reed) switch that prevents inappropriate programming of a pulse generator (“PG”), and in some cases, it can saturate the core of inductive switching power supplies, causing difficulties for some implantable device power supplies. Further, the time-varying gradient field can generate significant voltage in CRM device leads, which can cause false cardiac event sensing. Finally, some tests have shown that the RF field produced in MRI systems can cause CRM device heating, and voltage generation in the CRM device circuitry and leads. Of particular concern are the MR-induced voltages, which potentially can inhibit pacing and/or ICD defibrillation, or which can induce excessively rapid pacing and/or inappropriate ICD defibrillation shocks. Both of these malfunctions can be life-threatening events. Indeed, some deaths have been reported for patients with implanted CRM systems who were inadvertently subjected to MRI scans. As a result, both the U.S. Food and Drug Administration (FDA) and many pacemaker manufacturers have issued warnings against pacemaker recipients undergoing MRIs.


Also, as one skilled in the art will appreciate, the adverse effects of MRI fields are not limited to CRM devices. MRI fields can adversely affect other IMDs, as well. Thus, a need exists for systems, methods, and/or devices that can mitigate the hazards associated with using CRM devices and other IMDs in an MRI environment.


BRIEF SUMMARY OF THE INVENTION

One embodiment of the present invention relates to an implantable medical device (“IMD”) that can be programmed from one operational mode to another operational mode when in the presence of electro-magnetic interference (“EMI”). In accordance with this particular embodiment, the IMD includes a communication interface for receiving communication signals from an external device, such as a command to switch the IMD from a first operation mode to a second operation mode. The IMD further includes a processor in electrical communication with the communication interface, which is operable to switch or reprogram the IMD from the first operation mode to the second operation mode upon receiving a command to do so. In addition, the IMD includes a timer operable to measure a time period from when the processor switches the IMD to the second operation mode. In accordance with this aspect of the invention, the processor is in electrical communication with the timer, and is further operable to switch the IMD from the second operation mode back to the first operation mode when the measured time period reaches a predetermined time period. In one embodiment, the timer is separate from the processor, and in another embodiment, the processor can act as the timer.


In one embodiment, the IMD is a cardiac pacing device. Thus, in accordance with this embodiment, the first operation mode is a non-fixed-rate pacing mode, and the second operation mode is a fixed-rate pacing mode. In another embodiment, the first operation mode is can be a demand pacing mode, and the second operation mode can be a non-demand or asynchronous pacing mode


In another embodiment, the IMD is an implantable cardioverter defibrillator. Thus, in accordance with this embodiment, the first operation mode is a mode in which tachy therapy is enabled, and the second operation mode is a mode in which tachy therapy is disabled.


In one embodiment, the IMD is switched from the first operation mode to the second operation mode prior to a patient receiving a magnetic resonance imaging (MRI) scan, and the predetermined time period is set so that the implantable medical device is switched back to the first operation mode after the MRI scan is complete.


In accordance with another embodiment, the present invention is a cardiac rhythm management (CRM) device, which comprises a processor for executing computer program instructions, and a communication interface operable to receive communication signals from an external device and transmit the communication signals to the processor. The communication signals can include commands to switch or reprogram the CRM device between an MRI mode and a non-MRI mode. In one embodiment, the MRI mode can be a CRM device mode that allows the CRM device to switch from a normal operation mode to an MRI-safe operation mode in the presence of one or more MRI electromagnetic fields. Further, the non-MRI mode can be a CRM device mode that prohibits the CRM device from switching from the normal operation mode to the MRI-safe operation mode.


In accordance with this particular embodiment of the invention, the CRM device further comprises an electromagnetic field sensor, which is operable to measure electromagnetic fields generated by an MRI system and communicate the electromagnetic field measurements to the processor. In this embodiment, the CRM device is operable to configure itself in an MRI mode upon receiving a command from the external device to do so. Then, using the electromagnetic field sensor, the CRM device can determine whether the measured MRI electromagnetic fields are above or below a predetermined field strength threshold. If the MRI electromagnetic fields are above the predetermined threshold, the CRM device is operable to switch from its normal operation mode to an MRI-safe operation mode. The CRM device then will stay in the MRI-safe operation mode until the MRI electromagnetic fields drop below the predetermined level, at which time, the CRM device then will switch back to its normal operation mode. Finally, in accordance with this particular embodiment, the CRM device will switch out of the MRI mode upon receiving a command from an external device to do so.


In one embodiment, the CRM device is a cardiac pacing device. In this embodiment, the normal operation mode is a non-fixed-rate pacing mode, and the MRI-safe operation mode is a fixed-rate pacing mode. Further, in another embodiment, the CRM device is an implantable cardioverter defibrillator. Thus, in this embodiment, the normal operation mode is a mode in which tachy detection is enabled, and the MRI-safe operation mode is a mode in which tachy detection is disabled.


In other embodiments, the present invention relates to methods performed by the aforementioned devices. In still other embodiments, the present invention relates to other devices and methods for programming the devices into safe modes of operation as discussed in more detail below and as set forth in the claims.


A more complete understanding of the present invention may be derived by referring to the detailed description of preferred embodiments and claims when considered in connection with the figures.





BRIEF DESCRIPTION OF THE DRAWINGS

In the Figures, similar components and/or features may have the same reference label. Further, various components of the same type may be distinguished by following the reference label with a second label that distinguishes among the similar components. If only the first reference label is used in the specification, the description is applicable to any one of the similar components having the same first reference label irrespective of the second reference label.



FIG. 1 is a diagram showing the relationship between an implantable medical device and an MRI system in accordance with one embodiment of the present invention;



FIG. 2 is a block diagram of one embodiment of an implantable medical device that can be used in the present invention;



FIG. 3 is a block diagram of one embodiment of a telemetry system that can be used in the present invention; and



FIGS. 4-10 are flow charts illustrating different embodiments of methods of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to implantable medical devices (“IMDs”), and more particularly to systems, devices and methods for rendering IMDs more safe in the presence of strong electro-magnetic interference (“EMI”), such as those produced by magnetic resonance imaging (“MRI”) systems. In accordance with at least some embodiments, the present invention relates to IMDs that can be programmed to alter their operational modes in the presence of eletro-magnetic interference to prevent damage to the IMD and/or the patient. As discussed in more detail below, the IMDs can be programmed from an external programming device, or the IMDs can be configured to automatically change operational modes in the presence of the EMI.


As used herein, the term electro-magnetic interference (“EMI”) can refer to any EMI, such as static magnetic fields, gradient magnetic fields, and/or radio frequency (“RF”) fields generated by an MRI system, or any other electro-magnetic fields or interference that can be generated by any number of different sources, such as metal detectors, radio transmitters, cellular phones, microwave generators, electronic article surveillance systems, etc. Thus, the present invention can be used to render IMDs more safe in the presence of any EMI and is not limited to any particular EMI environment. As one skilled in the art will appreciate, however, operating IMDs during MRI scans or at least recognizing the presence of the IMDs prior to an MRI scan is of particular interest to health care providers. Thus, for this reason, and for ease of presentation, the present invention will be discussed with reference to MRI systems. The present invention, however, is not limited to an MRI environment.


Also, as discussed above, some embodiments of the invention relate to switching operational modes of the IMDs to render them more safe in the presence of EMI, and in particular, MRI fields. In these embodiments, the IMDs are switched from a “normal” operational mode to an “MRI-safe” operation mode. As one skilled in the art will appreciate, a normal operational mode is the operational mode of the IMD prior to it being altered in presence of EMI. Thus, for cardiac rhythm management devices (“CRM”), such as Brady and/or Tachy devices, for example, the normal operational mode is the CRM's initially programmed mode.


The term “MRI-safe” mode, as used herein, can refer to any operational mode of an IMD that is a safe operational mode in the presence of EMI. For example, for a Brady device (as well as a Brady engine in a Tacky device) an MRI-safe mode might be a fixed-rate and/or non-demand (or asynchronous) pacing mode as opposed to a rate-responsive and/or demand pacing mode. In some embodiments, an MRI-safe mode can be both a non-demand mode (i.e., VOO) and a non-rete-responsive mode. Thus, in accordance with one embodiment, switching a Brady device to an MRI-safe mode might entail switching the Brady engine to a VOO, AOO or DOO pacing mode. The mode to which the device is switched will depend, of course, on the original programmed mode of the device. In one embodiment, a device, which is normally programmed to a Dxx mode (i.e., DDDR, DDD, DDI, or DVI) would switch to DOO when in MRI-safe mode. Similarly, a device programmed to Vxx mode would switch to VOO, and a device programmed to Axx mode would switch to AOO mode.


Further, in other embodiments, an MRI-safe mode for a Tacky device might comprise turning-off tacky detection and/or therapy, as well as switching the Brady engine of the Tacky device to a fixed-rate, non-demand pacing mode. In these embodiments, turning the tacky detection off will ensure that noise that might be induced on the device leads by an MRI scan is not mistaken by the device for tachycardia, which might result in an inappropriate shock during an MRI. Also, for CRM devices, there may be other modes of operation that are considered safe in an MRI environment, so the present invention is not limited to the MRI-safe modes discussed herein. Further, as one skilled in the art will appreciate, other types of IMDs will have different mode types that might be considered safe in an MRI environment, and those modes also are considered MRI-safe modes for purposes of the present invention.


Referring now to FIG. 1, diagram 100 illustrates an MRI system environment in which it can be beneficial to detect the presence of an IMD and alter the processing of the MRI system and/or the IMD to prevent damage to the IMD and/or the patient with the IMD. This particular diagram illustrates a patient 110 having an IMD 120 in the presence of an MRI system 130. In this particular embodiment, MRI system 130 includes a telemetry system 140, which is operable to communicate wirelessly (e.g., wireless link 160) with IMDs. Telemetry system 140 can be integral with MRI system 130, or telemetry system 140 can be a separate device in communication with MRI system 130, for example, via a USB connection, a firewire connection, a network, or any other suitable communication connection. In addition, as illustrated in diagram 100, IMD 120 further is operable to wirelessly communicate (e.g., wireless connection 170) with an external programming device 150, which can collect information from IMD 120, as well as reprogram IMD 120.


Thus, as discussed in more detail below, in some embodiments, MRI system 130 can detected the presence of an IMD 120 (e.g., using telemetry system 140), and then prevent MRI scans if the IMD is not in a safe mode of operation. In other embodiments, IMD 120 can be operable to detect the presence of EMI (for example magnetic and/or RF signal from MRI system 130) and then alter its programming (either automatically, or manually via external programming device 150) to put the IMD in a safe mode of operation. In still other embodiments, IMD 120 can be operable to detect the presence of MRI system 130, and then send commands or information to MRI system 130, disabling MRI scans until the IMD can be programmed into a safe mode of operation. In still other embodiments, IMD 120 can be manually programmed (e.g. via external programming device 150) into safe modes of operation prior to being exposed to EMI, such as MRI scans, or the like. The inter-working relationships between IMD 120 and MRI system 130, telemetry system 140 and external programming device 150 will be discussed in more detail below.


In accordance with the present invention, IMD 120 can be any type of implantable medical device that might be affected by EMI, and in particular, MRI scans. For example, IMD 120 can be a pacemaker, an implantable cardioverter defibrillator (“ICD”), a cardiac resynchronization device, a bi-ventricular pacer, a ventricular assist blood pump, a drug delivery pump, a drug infusion device, a neurostimulating device, an intra-ocular shunt, an intra-cranial shunt, or any other suitable implantable device that might be sensitive to EMI. In the embodiment illustrated in FIG. 1, IMD 120 is a cardiac device, such as a pacemaker, an ICD, or the like.


Referring now to FIG. 2, one embodiment of an IMD 120 is illustrated. In accordance with the illustrated embodiment, IMD 120 comprises a processor 202, a memory 204, communication circuitry 206, therapy circuitry 208 and sensor circuitry 210, timer circuitry 212, and an EMI detector 214. In this particular embodiment, memory 204, communication circuitry 206, therapy circuitry 208, sensor circuitry 210, timer circuitry 212, and EMI detector 214 all are in electrical communication with processor 202, as is illustrated by the arrows in FIG. 2.


The embodiment of IMD 120 illustrated in FIG. 2 is merely one exemplary embodiment of an IMD. One skilled in the art will appreciate that other IMDs might include more features or functionality not shown in FIG. 2, or other IMDs might include less features and/or functionality. For example, some IMDs might not provide therapy, so therapy circuitry 208 might not be present. Further, as discussed below, having both timer circuitry 212 and EMI 214 might not be needed in all embodiments, so IMD 120 may be configured without one or both of those features. Thus, the present invention is not limited to the IMD illustrated in FIG. 2.


As one skilled in the art will appreciate, processors and memory devices are well known in the art, and the specific type and/or style of processor or memory device that can be used in IMD 120 is not limited. Accordingly, processor 202 can be any suitable processing device currently known or hereinafter developed, and memory device 204 can be any suitable memory device currently known or hereinafter developed.


Communication circuitry 206 is circuitry that allows IMD 120 to communicate with other devices, such as external programming device 160, telemetry system 140, other IMDs, or other external devices. As discussed above, IMD 120 can communicate with other devices via a wireless connection. The wireless connection can be, for example, a near field radio frequency (RF) communication connection, a far field RF communication connection, an acoustic communication connection (e.g., an ultrasound connection), an optical communication connection, or any other suitable wireless communication connection.


In one embodiment, communication circuitry 206 can include circuitry for both near field RF telemetry and far field RF telemetry. For example, various embodiments of communication circuitry that can be used in IMD 120 are disclosed in Published U.S. Patent App. No. US 2003/0114897 A1, published on Jun. 19, 2003, and entitled “Implantable Medical Device with Two or More Telemetry Systems,” and Published U.S. Patent App. No. U.S. 2003/0114898 A1, published on Jun. 19, 2003, and entitled “Telemetry Duty Cycle Management System for an Implantable Medical Device,” both of which are incorporated by reference herein for all purposes.


In addition, in other embodiments, power saving wireless communication circuitry and methods can be used. For example, the IMD communication circuitry 206 can be configured to reside in a power-saving, sleep mode for a majority of the time. In accordance with this embodiment, communication circuitry 206 can be configured to “wake-up” on a periodic basis to communicate with an external device. Upon “wake-up” the external device will monitor for RF activity, and if the external device locates it, communication between the IMD and the external device can be initiated. There are a number of different ways IMD power-saving modes can be implemented, and the present invention is not limited to any particular one. Indeed, the aforementioned Published U.S. Patent App. Nos. US 2003/0114897 A1 and US 2003/0114898 A1 disclose different ways of implementing IMD power-saving modes, which, as discussed above, are incorporated herein by reference for all purposes. In addition, additional power management systems and methods are disclosed in Published U.S. Patent App. No. US 2003/0149459 A1, published on Aug. 7, 2003, and entitled “Methods and Apparatuses for Implantable Medical Device Telemetry Power Management” and Published U.S. Patent App. No. US 2002/0147388 A1, published on Oct. 10, 2002, and entitled “Passive Telemetry for Implantable Medical Device,” both of which are incorporated by reference herein for all purposes.


Further, in accordance with other embodiments, communication circuitry 206 can be configured to communicate with an intermediary telemetry device, which, in turn, can facilitate communication with the external monitoring device 104 and/or external computing device 106. One example of this type of configuration is disclosed in Published U.S. Patent App. No. US 2003/0130708, published on Jul. 10, 2003, and entitled “Two-Hop Telemetry Interface for Medical Device,” the entirety of which is incorporated by reference herein for all purposes. In addition, other configurations for RF telemetry are known, and communication circuitry 206 can embody those configurations, as well. Thus, as one skilled in the art will appreciate, communication circuitry 206 is not limited by any particular configuration or communication means.


Therapy circuitry 208 comprises circuitry for providing one or more therapeutic functions to a patient. For example, therapy circuitry 208 can include circuitry for providing heart pacing therapy, cardiac defibrillation therapy, cardiac resynchronization therapy, drug delivery therapy, or any other therapy associated with a suitable IMD. In the case of cardiac therapy (e.g., pacing, defibrillation, etc.), therapy circuitry 208 can include cardiac leads for delivering the therapy to particular locations in the heart. In other embodiments, the therapy circuitry and/or therapy delivery mechanisms can reside in a satellite device wirelessly coupled to the IMD body 120, as discussed below.


Sensor circuitry 210 comprises the sensors and circuitry needed to obtain or measure one or more physiologic parameters. For example, to obtain a blood pressure (e.g., intravascular or intracardiac blood pressure), sensor circuitry 210 comprises one or more pressure sensors and associated circuitry for recording the pressure accurately. Pressure sensors and the associated circuitry are well known in the art, and therefore, will not be disclosed in detail herein. In addition, in other embodiments, sensor circuitry 210 can be configured to obtain other physiologic parameters, such as temperature, electrical impedance, position, strain, pH, fluid flow, blood oxygen levels, and the like. In these cases, sensor circuitry 210 will include suitable bio-sensors for obtaining the corresponding physiologic parameters. Also, as one skilled in the art will appreciate, the sensors and/or sensor circuitry can be, and many times are, electrically coupled to IMD 120, but placed remotely from the IMD; e.g., at the end of a lead or in a satellite device in wireless communication with IMD 120.


In an alternative embodiment, IMD 120 can comprise a planet/satellite configuration, in which the satellite portion of the IMD includes sensor and/or therapy delivery circuits and mechanisms. Such a configuration is disclosed in Published U.S. Patent Application No. US 2003/0158584 A1, published on Aug. 21, 2003, and entitled “Chronically-Implanted Device for Sensing and Therapy,” the entirety of which is incorporated herein by reference for all purposes. In this system, the planet or main body of the IMD communicates with one or more satellite sensor/therapy devices either by an electrical wire connection or wirelessly. In some embodiments, the planet or main body can command each satellite to provide sensing functions and therapy functions, such as delivering cardiac electrical pulses, drug delivery, or other functions, as discussed above. In other embodiments, the satellite devices can function autonomously, and then communicate with the planet device at their own direction, at the planet's direction, or at timed intervals. The relationships between the planet device and the satellite device(s) are discussed in more detail in the incorporated reference.


Timer circuitry 212 can comprise any suitable circuitry and/or functionality for tracking time periods. Timer circuitry can be a separate timer circuit, as illustrated in FIG. 2, or the timing functionality can be performed, for example, by processor 202. As one skilled in the art will appreciate, timers are well known in the art, and the particular circuitry that performs the timing functionality is not important. Thus, the present invention is not limited to any particular timer embodiment. The use of a timer and/or timer circuitry 212 will be discussed in greater detail below.


Finally, EMI detector 214 can comprise one or more detectors for detecting electro-magnetic fields and/or radiation. For example, EMI detector 214 can include a sensor for detecting the presence and/or strength of magnetic fields, such as a Hall-effect sensor, or other suitable magnetic field detectors currently known or hereinafter developed. In addition, EMI detector 214 can further include sensors for detecting the presence of high-frequency radiation that can be produced by MRI systems, radar, radio transmitters, and the like. Again, the purpose and use of EMI detector 214 will be discussed in greater detail below.


Referring now to FIG. 3, one embodiment of a telemetry system 140 that can be associated with MRI system 130 is shown. As discussed above, telemetry system 140 is operable to communicate with IMDs that might be near MRI system 130. In the illustrated embodiment, telemetry system 140 comprises a processor 300, an RF transmitter 310, and RF receiver 320, a transmit/receive (“T/R”) switch 330 and an antenna 340. In this particular embodiment, processor 300 is interfaced to RF transmitter 310 and RF receiver 320, both of which are connected to antenna 340. T/R switch 330 passes RF signals uni-directionally from transmitter 310 to antenna 340 and from antenna 340 to the receiver 320. To communicate data to an IMD, processor 300 sends data to transmitter 310, which generates an RF carrier signal for a specified time period that is emitted from the antenna 340. As one skilled in the art will appreciate, the carrier signal includes the data to be transmitted to the IMD. The transmitted carrier signal then reaches the IMD, which, in turn, receives and processes the data. Similarly, when communicating data or information from the IMD to telemetry circuitry 140, the communication circuitry 206 of the IMD is operable to generate and transmit an RF carrier signal to antenna 340. After reaching antenna 340, the carrier signal is conveyed through T/R switch 330 to receiver 320, where the signal is demodulated to extract the digital message data. The digital data may then be processed and interpreted by software executed by the processor 300.


T/R switch 330 of the telemetry circuitry enables receiver 320 to receive signals without having to recover from saturation from signals that were previously emitted by antenna 340 that originate from transmitter 310. As an alternative to the T/R switch, a directional coupler could be used to separate the transmit and receive signals, or separate antennas with orthogonal linear polarization states can be provided for the transmitter and receiver, thus enabling simultaneous radiation of the carrier signal by the transmitter antenna and reception of the reflected carrier by the receiver antenna.


A more complete description of near-field and far-field telemetry is set forth in the patents incorporated by reference above. As one skilled in the art will appreciate, the present invention is not limited to any specific telemetry circuitry or functionality.


Referring again to FIG. 1, external programming device 150 can be any suitable computing device adapted to communicate with IMD 120 and/or telemetry circuitry 140 and process data from those devices. For example, in the case of a cardiac rhythm management (“CRM”) IMD (e.g., pacemaker, ICD, etc.), external programming device 150 might be a programmer used by physicians, specialists, or other health care providers to extract data from and program cardiac IMDs. Programmers are well known in the art. In addition, in other embodiments, external programming device 150 can be a repeater device associate with a patient. Examples of one or more repeater-type devices are disclosed in U.S. Pat. No. 6,607,485, issued on Aug. 9, 2003, and entitled “Computer Readable Storage Medium Containing Code for Automated Collection and Analysis of Patient Information Retrieved from an Implantable Medical Device for Remote Patient Care,” the entirety of which is incorporated by reference herein for all purposes.


Referring now to FIG. 4, flow chart 400 illustrates one embodiment of a method for programming an IMD in a safe mode of operation while in the presence of MRI systems or other EMI. In accordance with the method illustrated in flow chart 400, an IMD (e.g., IMD 120 in FIG. 1) receives a command from an external programming device to switch to a safe mode of operation (e.g., an MRI-safe mode as discussed above) (block 402). The external programming device could be external programming device 150, or the external programming device could be associated with MRI system 130 and could communicate with the IMD via a telemetry interface, such as telemetry system 140.


Upon receiving a command to switch to a safe mode of operation, a processor within the IMD (e.g., processor 202 of IMD 120) will program the IMD's operational mode to safe mode (block 404), and then a timer within the IMD (e.g., timer 212 of IMD 120) will begin measuring a time period from when the reprogram occurs (block 406). When the MRI or other EMI exposure is complete, the IMD can be manually programmed back to a normal mode of operation by sending it a command to do so. In accordance with this particular embodiment, the purpose of the timer is to ensure that the IMD does not remain in the safe mode of operation for extended periods of time (e.g., should the operator forget to send the manual command to return the device to normal mode), because generally, it is in the patient's best interest to have the IMD operating in its normal mode of operation as originally programmed. The IMD's safe mode of operation should be limited to time periods when the IMD is in the presence of EMI, such as MRI scans, and the like. Thus, after the timer reaches a predetermined time (e.g., a time period after an MRI scan is complete), if the IMD has not received a command to switch back to normal mode of operation, the IMD is switched back from the safe mode of operation to its normal mode of operation (block 408). As discussed above, the processor within the IMD can be operable to reprogram the IMD's operation mode switch.


Referring now to FIG. 5, flow chart 500 illustrates another embodiment of a method for programming an IMD in a safe mode of operation while in the presence of MRI systems or other EMI. In accordance with the method illustrated in flow chart 500, an IMD (e.g., IMD 120 in FIG. 1) receives a command from an external programming device to reprogram to an MRI-mode of operation (block 502). The external programming device could be external programming device 150, or the external programming device could be associated with MRI system 130 and could communicate with the IMD via a telemetry interface, such as telemetry system 140.


In accordance with this particular embodiment of the invention, the MRI-mode of operation is not a “safe mode” in which a Brady device is set to a fixed-rate, non-demand pacing mode or tacky detection or therapy of a tacky device is disabled, as discussed above. In accordance with this particular embodiment, the MRI-mode of operation is a pre-MRI scan setting in which a magnetic field detector is activated (e.g., EMI detector 214 of IMD 120 in FIG. 2). Thus, when the magnetic field detector of the IMD detects a magnetic field of sufficient strength (i.e., in the presence of an MRI system) (block 504), the IMD will automatically switch to a safe mode of operation (block 506), as defined above. Once in safe mode, the magnetic field detector of the IMD will continue to monitor for the presence and/or absence of the magnetic field (block 508). When the magnet field has dissipated to safe level, the IMD will automatically switch back to its normal mode of operation (block 510).


Further, as one skilled in the art will appreciate, it can be unsafe to have an IMD operating in the MRI-mode of operation for long periods of time, because the IMD will automatically switch to a safe mode in the presence of magnetic fields, even when it is not necessary or desirable to have the IMD in the safe mode. Thus, in accordance with this particular embodiment, after an MRI scan is complete or after the IMD is positioned a safe distance from strong EMI, the IMD can be taken out of the MRI-mode of operation by receiving a command from an external programming device and processing the command (block 512).


Referring now to FIG. 6, flow chart 600 illustrates an embodiment of a method for operating an IMD in a safe mode of operation while in the presence of EMI. In accordance with the method illustrated in flow chart 600, an IMD (e.g., IMD 120 in FIG. 1) includes an EMI detector (EMI detector 214 in FIG. 2), which is operable to detect EMI, such as magnetic fields and/or RF energy (block 602). Thus, when the magnetic field detector of the IMD detects a magnetic field of sufficient strength (e.g., in the presence of an MRI system), the IMD will automatically switch to a safe mode of operation, as defined above (block 604), and then a timer within the IMD (e.g., timer 212 of IMD 120) will begin measuring a time period from when the switch to safe mode occurs (block 606). As discussed above, the purpose of the timer is to ensure that the IMD does not remain in the safe mode of operation for extended periods of time. Thus, after the timer reaches a predetermined time (e.g., a time period after the IMD is a safe distance from the EMI), the IMD is switched back from the safe mode of operation to its normal mode of operation (block 608). As discussed above, the processor within the IMD can be operable to reprogram the IMD's operation mode switches.


Referring now to FIG. 7a, flow chart 700 illustrates another embodiment of a method for programming an IMD in a safe mode of operation while in the presence of MRI systems or other EMI. In accordance with the method illustrated in flow chart 700, an IMD (e.g., IMD 120 in FIG. 1) receives a command from an external programming device to switch to an MRI-mode of operation, which is discussed above (block 702). The external programming device could be external programming device 150, or the external programming device could be associated with MRI system 130 and could communicate with the IMD via a telemetry interface, such as telemetry system 140.


As discussed above, the MRI-mode of operation is a pre-MRI scan setting in which a magnetic field detector is activated (e.g., EMI detector 214 of IMD 120 in FIG. 2). Thus, when the magnetic field detector of the IMD detects a magnetic field of sufficient strength (i.e., in the presence of an MRI system) (block 704), the IMD will automatically switch to a safe mode of operation (block 706), as defined above. Once in safe mode, a timer within the IMD (e.g., timer 212 of IMD 120) will begin measuring a time period from when the switch to safe mode occurs (block 708). As discussed above, the purpose of the timer is to ensure that the IMD does not remain in the safe mode of operation for extended periods of time. Thus, after the timer reaches a predetermined time (e.g., a time period after an MRI scan is has completed), the IMD is switched back from the safe mode of operation to its normal mode of operation (block 710).


After an MRI scan is complete or after the IMD is positioned a safe distance from strong EMI, the IMD can be taken out of the MRI-mode of operation (block 712). In one embodiment, the IMD can be taken out of the MRI-mode of operation by receiving a command from an external programming device and processing the command, as discussed above with reference to FIG. 5. In an alternative embodiment illustrated in FIG. 7b, instead of using an external programming device to switch the IMD out of MRI-mode, a timer can be used. In this particular embodiment, after the IMD is switched back to normal operation mode (block 710), a timer within the IMD (e.g., timer 212 of IMD 120) will begin measuring a time period from when the switch to normal mode occurs (block 720). Then, after the timer reaches a predetermined time, the IMD automatically is switched out of the MRI-mode of operation (block 722), so that it will not accidentally detect EMI and switch into safe mode again.


Referring now to FIG. 8, flow chart 800 illustrates yet another embodiment of a method of operating an IMD in a safe mode of operation while in the presence of MRI systems or other EMI. In accordance with the method illustrated in flow chart 800, an IMD (e.g., IMD 120 in FIG. 1) is operable to measure one or more electromagnetic field components generated by an MRI system, such as the strength of a static magnetic field (block 802), and/or the amplitude of RF signals at a predetermined frequency (block 804). In accordance with this aspect of the invention, the IMD can comprise one or more detectors for detecting the static magnetic field and/or the RF amplitude. In one embodiment, a single EMI detector (e.g., EMI detector 214 in FIG. 1) can be used to measure both the magnetic field and/or the RF amplitude. In an alternative embodiment, a hall effect sensor can be used to measure the magnetic field, and an RF sensor or detector can be used to measure the amplitude of the RF signals. As one skilled in the art will appreciate, a band pass or notch filter can be used to select the frequency at which the amplitude of the RF signal is measured. In one embodiment, the RF signal amplitude can be measured at about 64 MHz. In other embodiments, the RF signal can be measured at other frequencies.


In one embodiment, measuring the magnetic field and the RF amplitude can provide redundant measurements, so that an IMD will not switch to safe mode unless both conditions are met (if both conditions are met, the IMD most likely is near an MRI system). Thus, if the magnetic field exceeds a predetermined strength threshold (e.g., about 0.001 Tesla, or so), and/or the RF signal exceeds an amplitude threshold (e.g., about 0.2 mT per meter) at the particular frequency, the IMD automatically will switch to a safe mode of operation, as defined above (step 806). Once in safe mode, the IMD will continue to monitor the magnetic field and/or the RF signal amplitude at the predetermined frequency (blocks 808 and 810). When the magnetic field has dissipated to a safe level (e.g., below 0.001 T or less than 1% of the full field strength) and/or the RF signal amplitude drops, the IMD will automatically switch back to its normal mode of operation (block 812). While this particular embodiment uses both the static magnetic field strength and RF amplitude measurements, one skilled in the art will appreciate that other embodiments might only measure and use one of the measurements, or other electromagnetic field components can be used. Thus, the present invention is not limited to any one particular embodiment.


Referring now to FIG. 9, flow chart 900 illustrates yet another embodiment of a method of operating an IMD in a safe mode of operation while in the presence of MRI systems or other EMI. In accordance with the method illustrated in flow chart 900, an IMD is operable to measure the strength of a static magnetic field generated by an MRI system (block 902). In addition, the IMD is operable to measure the amplitude of RF signals generated by the MRI system at a predetermined frequency (block 904). These steps are similar to steps discussed above with reference to FIG. 8. Again, if the magnetic field exceeds a predetermined strength threshold, and the RF signal exceeds an amplitude threshold at the particular frequency, the IMD automatically will switch to a safe mode of operation (step 906). Next, the IMD sets a predetermined time period and starts a timer (block 908). The IMD then will continue to monitor the magnetic field and/or the RF signal amplitude at the predetermined frequency (blocks 910). If the magnetic field continues to exceed the predetermined strength and the RF signal continues to exceed the predetermined amplitude, the predetermined time period is extended by an incremental amount (block 912). Otherwise, the time period is not extended. Next, the timer is checked to determine if it has reached or passed the predetermined time period (decision block 914). If not, steps 910-914 are repeated. If the timer has reached or passed the predetermined time period, then the IMD will automatically switch back to its normal mode of operation (block 916).


Referring now to FIG. 10, flow chart 1000 illustrates yet another embodiment of a method for safely operating an IMD in the presence of an MRI system. In accordance with this particular embodiment, the MRI system (e.g., MRI system 130 in FIG. 1) detects the presence of an IMD (block 1002). As discussed above, a telemetry system (e.g., telemetry system 140 in FIG. 1) associated with the MRI system can detect IMDs using wireless communications, such as near field and/or far field RF telemetry. Alternatively, in another embodiment, instead of the telemetry system detecting the presence of the IMD, the IMD can be operable to detect the presence of an MRI magnetic field and then communicate with the telemetry system associated with the MRI system, informing the MRI system that the IMD is present.


Once the MRI System and the IMD initiate communications, the MRI system can receive information about the IMD via the telemetry link. In one embodiment, the MRI system receives at least some data from the IMD indicating whether the IMD is in a safe mode of operation, as defined above (block 1004). If the IMD is in a safe mode of operation (decision block 1006), the MRI system can proceed with an MRI scan (block 1008). Alternatively, if the IMD is not in a safe mode of operation, one or more functions may occur (which is illustrated as alternative block 1010).


In one embodiment, if the IMD is not in a safe mode of operation, the MRI system or the telemetry system associated with the MRI system can send an alarm message to the MRI operator, informing the operator that a non-safe IMD is present (block 1012). Alternatively, in another embodiment, instead of sending an alarm message to the MRI operator, the MRI system can be operable to automatically prevent MRI scans from occurring when an IMD is present, but not in a safe mode of operation (block 1012). In yet another embodiment, the MRI system can be operable to send an alarm and disable MRI scan functionality.


In yet another embodiment of the invention, if an IMD is not in a safe mode of operation, the MRI system and/or the telemetry system associated with the MRI can transmit a command wirelessly to the IMD instructing it to switch to a safe mode of operation (block 1014). After the IMD switches to a safe mode of operation, the MRI system then can conduct an MRI scan (1016). In some embodiment, the telemetry system and/or the MRI system will wait for a message from the IMD confirming that the IMD switched to a safe mode of operation prior to conducting the MRI scan. Upon completion of the MRI scan, the MRI system, then can send a command to the IMD instructing it to switch back to its normal mode of operation, which the IMD will do upon receiving the command (block 1018).


In conclusion, the present invention provides novel systems, methods and devices for mitigating the hazards associated with using IMDs in the presence if EMI, and in particular, in MRI environments. While detailed descriptions of one or more embodiments of the invention have been given above, various alternatives, modifications, and equivalents will be apparent to those skilled in the art without varying from the spirit of the invention. Therefore, the above description should not be taken as limiting the scope of the invention, which is defined by the appended claims.

Claims
  • 1. A method for operating an implantable medical device (IMD) in the presence of a magnetic resonance imaging (MRI) system, the IMD including a sensor operable to sense MRI electromagnetic fields, the method comprising: programming the IMD with an external device from a non-MRI mode, in which the sensor is inactive, to an MRI mode, in which the sensor is active, outside the presence of the MRI system; andswitching the IMD from a first operation mode to a second operation mode when the sensor detects an MRI electromagnetic field.
  • 2. The method of claim 1, and further comprising: measuring a time period from when the IMD is switched to the second operation mode; andswitching the IMD from the second operation mode to the first operation mode when the measured time period reaches a predetermined time period.
  • 3. The method of claim 2, wherein the predetermined time period is extended if the sensor detects an MRI electromagnetic field at the end of the predetermined time period.
  • 4. The method of claim 1, wherein the IMD is a cardiac pacing device, and wherein the first operation mode is a non-fixed-rate pacing mode, and the second operation mode is a fixed-rate pacing mode.
  • 5. The method of claim 1, wherein the IMD is a cardiac pacing device, and wherein the first operation mode is a demand pacing mode, and the second operation mode is a non-demand or asynchronous pacing mode.
  • 6. The method of claim 1, wherein the IMD is an implantable cardioverter defibrillator, and wherein the first operation mode is a mode in which tachy therapy is enabled, and the second operation mode is a mode in which tachy therapy is disabled.
  • 7. The method of claim 1, and further comprising: detecting the absence of the MRI electromagnetic fields;upon detecting the absence of the one or more MRI electromagnetic fields, switching the IMD from the second operation mode back to the first operation mode.
  • 8. The method of claim 1, and further comprising: programming the IMD from the MRI mode to the non-MRI mode, wherein in the non-MRI mode the IMD is prohibited from switching from the first operation mode to the second operation mode.
  • 9. A method for operating an implantable medical device (IMD) in the presence of electromagnetic interference (EMI), the IMD including a sensor operable to sense EMI, the method comprising: programming the IMD with an external device from a non-MRI mode, in which the sensor is inactive, to an MRI mode, in which the sensor is active, outside the presence of the EMI;detecting the presence of EMI;switching the IMD from a first operation mode to a second operation mode upon detecting the presence of EMI;measuring a time period from when the IMD is switched from the first operation mode to the second operation mode; andswitching the IMD from the second operation mode back to the first operation mode when the measured time period reaches a predetermined time period, wherein the predetermined time period is set so that the IMD is switched from the second operation mode back to the first operation mode after the IMD is positioned a safe distance from the EMI.
  • 10. The method of claim 9, wherein the IMD is a cardiac pacing device, and wherein the first operation mode is a non-fixed-rate pacing mode, and the second operation mode is a fixed-rate pacing mode.
  • 11. The method of claim 9, wherein the IMD is a cardiac pacing device, and wherein the first operation mode is a demand pacing mode, and the second operation mode is a non-demand or asynchronous pacing mode.
  • 12. The method of claim 9, wherein the IMD is an implantable cardioverter defibrillator, and wherein the first operation mode is a mode in which tachy therapy is enabled, and the second operation mode is a mode in which tachy therapy is disabled.
  • 13. The method of claim 9, wherein the EMI comprises electromagnetic signals from a magnetic resonance imaging (MRI) system, and wherein the step of switching the IMD from the first operation mode to the second operation mode is performed prior to a patient receiving an MRI scan, and wherein the predetermined time period is set so that the step of switching the IMD from the second operation mode back to the first operation mode is performed after the MRI scan is complete.
  • 14. A method for operating an implantable medical device (IMD) in the presence of a magnetic resonance imaging (MRI) system, the IMD including a sensor operable to sense electromagnetic fields, the method comprising: programming the IMD with an external device from a non-MRI mode, in which the sensor is inactive, to an MRI mode, in which the sensor is active, outside the presence of the MRI system;measuring a level of one or more electromagnetic field components generated by the MRI system;switching the IMD from a first operation mode to a second operation mode if the level of the one or more electromagnetic field components exceeds a predetermined level threshold;measuring the level of the one or more electromagnetic field components while the IMD is in the second operation mode; andswitching the IMD from the second operation mode to the first operation mode if the level of the one or more electromagnetic field components fall below the predetermined level threshold.
  • 15. The method of claim 14, and further comprising: starting a timer after the IMD is switched from the first operation mode to the second operation mode;switching the IMD from the second operation mode back to the first operation mode after the time period measured by the timer reaches a predetermined time period.
  • 16. The method of claim 15, and further comprising: extending the predetermined time period if the level of the one or more electromagnetic field components exceed the predetermined level threshold at the end of the predetermined time period.
  • 17. The method of claim 14, and further comprising: programming the IMD from the MRI mode to the non-MRI mode, wherein in the non-MRI mode the IMD is prohibited from switching from the first operation mode to the second operation mode.
  • 18. The method of claim 14, wherein measuring the level of the one or more electromagnetic field components comprises at least one of measuring a strength of a static magnetic field, measuring an amplitude of a radio frequency (RF) signal at a predetermined frequency, and measuring a strength of a static magnetic field and the amplitude of a RF signal at a predetermined frequency
  • 19. The method of claim 18, wherein measuring the amplitude of the RF signal comprises using a bandpass filter to select the RF signal at the predetermined frequency.
  • 20. The method of claim 19, wherein the predetermined frequency is about 64 MHz.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a division of U.S. patent application Ser. No. 11/015,807, filed Dec. 17, 2004, now U.S. Pat. No. 8,014,867, issued on Sep. 6, 2011, which is hereby incorporated by reference in its entirety.

US Referenced Citations (318)
Number Name Date Kind
3888260 Fischell Jun 1975 A
3898995 Dresbach Aug 1975 A
4091818 Brownlee et al. May 1978 A
4379459 Stein Apr 1983 A
4404125 Abolins et al. Sep 1983 A
4516579 Irnich May 1985 A
4611127 Ibrahim et al. Sep 1986 A
4694837 Blakeley et al. Sep 1987 A
4729376 DeCote, Jr. Mar 1988 A
4751110 Gulla et al. Jun 1988 A
4779617 Whigham Oct 1988 A
4823075 Alley Apr 1989 A
4869970 Gulla et al. Sep 1989 A
4934366 Truex et al. Jun 1990 A
5038785 Blakeley et al. Aug 1991 A
5075039 Goldberg Dec 1991 A
5076841 Chen et al. Dec 1991 A
5120578 Chen et al. Jun 1992 A
5187136 Klobucar et al. Feb 1993 A
5188117 Steinhaus et al. Feb 1993 A
5197468 Proctor et al. Mar 1993 A
5217010 Tsitlik et al. Jun 1993 A
5243911 Dow et al. Sep 1993 A
5279225 Dow et al. Jan 1994 A
5288313 Portner Feb 1994 A
5292342 Nelson et al. Mar 1994 A
5309096 Hoegnelid May 1994 A
5325728 Zimmerman et al. Jul 1994 A
5345362 Winkler Sep 1994 A
5391188 Nelson et al. Feb 1995 A
5406444 Selfried et al. Apr 1995 A
5424642 Ekwall Jun 1995 A
5438900 Sundstrom Aug 1995 A
5454837 Lindegren et al. Oct 1995 A
5470345 Hassler et al. Nov 1995 A
5523578 Herskovic Jun 1996 A
5527348 Winkler et al. Jun 1996 A
5529578 Struble Jun 1996 A
5545187 Bergstrom et al. Aug 1996 A
5562714 Grevious Oct 1996 A
5607458 Causey, III et al. Mar 1997 A
5609622 Soukup et al. Mar 1997 A
5618208 Crouse et al. Apr 1997 A
5620476 Truex et al. Apr 1997 A
5647379 Meltzer Jul 1997 A
5649965 Pons et al. Jul 1997 A
5650759 Hittman et al. Jul 1997 A
5662694 Lidman et al. Sep 1997 A
5683434 Archer Nov 1997 A
5687735 Forbes et al. Nov 1997 A
5694952 Lidman et al. Dec 1997 A
5697958 Paul et al. Dec 1997 A
5709225 Budgifvars et al. Jan 1998 A
5714536 Ziolo et al. Feb 1998 A
5722998 Prutchi et al. Mar 1998 A
5727552 Ryan Mar 1998 A
5735884 Thompson et al. Apr 1998 A
5749910 Brumwell et al. May 1998 A
5751539 Stevenson et al. May 1998 A
5759197 Sawchuk et al. Jun 1998 A
5764052 Renger Jun 1998 A
5766227 Nappholz et al. Jun 1998 A
5776168 Gunderson Jul 1998 A
5782891 Hassler et al. Jul 1998 A
5792201 Causey, III et al. Aug 1998 A
5800496 Swoyer et al. Sep 1998 A
5800497 Bakels et al. Sep 1998 A
5814090 Latterell et al. Sep 1998 A
5817130 Cox et al. Oct 1998 A
5827997 Chung et al. Oct 1998 A
5853375 Orr Dec 1998 A
5867361 Wolf et al. Feb 1999 A
5869078 Baudino Feb 1999 A
5870272 Seifried et al. Feb 1999 A
5871509 Noren Feb 1999 A
5877630 Kraz Mar 1999 A
5895980 Thompson Apr 1999 A
5905627 Brendel et al. May 1999 A
5959829 Stevenson et al. Sep 1999 A
5964705 Truwit et al. Oct 1999 A
5968854 Akopian et al. Oct 1999 A
5973906 Stevenson et al. Oct 1999 A
5978204 Stevenson Nov 1999 A
5978710 Prutchi et al. Nov 1999 A
5999398 Makl et al. Dec 1999 A
6008980 Stevenson et al. Dec 1999 A
6031710 Wolf et al. Feb 2000 A
6032063 Hoar et al. Feb 2000 A
6055455 O'Phelan et al. Apr 2000 A
6079681 Stern et al. Jun 2000 A
6101417 Vogel et al. Aug 2000 A
6147301 Bhatia Nov 2000 A
6161046 Maniglia et al. Dec 2000 A
6162180 Miesel et al. Dec 2000 A
6173203 Barkley et al. Jan 2001 B1
6188926 Vock Feb 2001 B1
6192279 Barreras, Sr. et al. Feb 2001 B1
6198968 Prutchi et al. Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6209764 Hartlaub et al. Apr 2001 B1
6217800 Hayward Apr 2001 B1
6235038 Hunter et al. May 2001 B1
6245464 Spillman et al. Jun 2001 B1
6246902 Naylor et al. Jun 2001 B1
6249701 Rajasekhar et al. Jun 2001 B1
6268725 Vernon et al. Jul 2001 B1
6270831 Kumar et al. Aug 2001 B2
6275369 Stevenson et al. Aug 2001 B1
6288344 Youker et al. Sep 2001 B1
6324431 Zarinetchi et al. Nov 2001 B1
6358281 Berrang et al. Mar 2002 B1
6365076 Bhatia Apr 2002 B1
6381494 Gilkerson et al. Apr 2002 B1
6421555 Nappholz Jul 2002 B1
6424234 Stevenson Jul 2002 B1
6446512 Zimmerman et al. Sep 2002 B2
6452564 Schoen et al. Sep 2002 B1
6456481 Stevenson Sep 2002 B1
6459935 Piersma Oct 2002 B1
6470212 Weijand et al. Oct 2002 B1
6487452 Legay Nov 2002 B2
6490148 Allen et al. Dec 2002 B1
6496714 Weiss et al. Dec 2002 B1
6503964 Smith et al. Jan 2003 B2
6506972 Wang Jan 2003 B1
6510345 Van Bentem Jan 2003 B1
6512666 Duva Jan 2003 B1
6522920 Silvian et al. Feb 2003 B2
6526321 Spehr Feb 2003 B1
6539253 Thompson et al. Mar 2003 B2
6545854 Trinh et al. Apr 2003 B2
6555745 Kruse et al. Apr 2003 B1
6563132 Talroze et al. May 2003 B1
6566978 Stevenson et al. May 2003 B2
6567259 Stevenson et al. May 2003 B2
6580947 Thompson Jun 2003 B1
6584351 Ekwall Jun 2003 B1
6595756 Gray et al. Jul 2003 B2
6607485 Bardy Aug 2003 B2
6626937 Cox Sep 2003 B1
6629938 Engvall et al. Oct 2003 B1
6631290 Guck et al. Oct 2003 B1
6631555 Youker et al. Oct 2003 B1
6640137 MacDonald Oct 2003 B2
6643903 Stevenson et al. Nov 2003 B2
6646198 Maciver et al. Nov 2003 B2
6648914 Berrang et al. Nov 2003 B2
6662049 Miller Dec 2003 B1
6673999 Wang et al. Jan 2004 B1
6711440 Deal et al. Mar 2004 B2
6713671 Wang et al. Mar 2004 B1
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6725092 MacDonald et al. Apr 2004 B2
6731979 MacDonald May 2004 B2
6795730 Connelly et al. Sep 2004 B2
6901292 Hrdlicka et al. May 2005 B2
6925328 Foster et al. Aug 2005 B2
6937906 Terry et al. Aug 2005 B2
6944489 Zeijlemaker et al. Sep 2005 B2
6963779 Shankar Nov 2005 B1
7013180 Dublin et al. Mar 2006 B2
7050855 Zeijlemaker et al. May 2006 B2
7076283 Cho et al. Jul 2006 B2
7082328 Funke Jul 2006 B2
7092756 Zhang et al. Aug 2006 B2
7123013 Gray Oct 2006 B2
7138582 Lessar et al. Nov 2006 B2
7164950 Kroll et al. Jan 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7174220 Chitre et al. Feb 2007 B1
7212863 Strandberg May 2007 B2
7231251 Yonce et al. Jun 2007 B2
7242981 Ginggen Jul 2007 B2
7272444 Peterson et al. Sep 2007 B2
7369898 Kroll et al. May 2008 B1
7388378 Gray et al. Jun 2008 B2
7509167 Stessman Mar 2009 B2
7561915 Cooke et al. Jul 2009 B1
7835803 Malinowski et al. Nov 2010 B1
7839146 Gray Nov 2010 B2
8014867 Cooke et al. Sep 2011 B2
8032228 Ameri et al. Oct 2011 B2
8086321 Ameri Dec 2011 B2
8160717 Ameri Apr 2012 B2
20010002000 Kumar et al. May 2001 A1
20010006263 Hayward Jul 2001 A1
20010011175 Hunter et al. Aug 2001 A1
20010018123 Furumori et al. Aug 2001 A1
20010025139 Pearlman Sep 2001 A1
20010037134 Munshi Nov 2001 A1
20010050837 Stevenson et al. Dec 2001 A1
20020019658 Munshi Feb 2002 A1
20020026224 Thompson et al. Feb 2002 A1
20020038135 Connelly et al. Mar 2002 A1
20020050401 Youker et al. May 2002 A1
20020072769 Silvian et al. Jun 2002 A1
20020082648 Kramer et al. Jun 2002 A1
20020102835 Stucchi et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020117314 Maciver et al. Aug 2002 A1
20020128689 Connelly et al. Sep 2002 A1
20020128691 Connelly Sep 2002 A1
20020133086 Connelly et al. Sep 2002 A1
20020133199 MacDonald et al. Sep 2002 A1
20020133200 Weiner et al. Sep 2002 A1
20020133201 Connelly et al. Sep 2002 A1
20020133202 Connelly et al. Sep 2002 A1
20020133208 Connelly Sep 2002 A1
20020133211 Weiner et al. Sep 2002 A1
20020133216 Connelly et al. Sep 2002 A1
20020138102 Weiner et al. Sep 2002 A1
20020138107 Weiner et al. Sep 2002 A1
20020138108 Weiner et al. Sep 2002 A1
20020138110 Connelly et al. Sep 2002 A1
20020138112 Connelly et al. Sep 2002 A1
20020138113 Connelly et al. Sep 2002 A1
20020138124 Helfer et al. Sep 2002 A1
20020143258 Weiner et al. Oct 2002 A1
20020147388 Mass et al. Oct 2002 A1
20020147470 Weiner et al. Oct 2002 A1
20020162605 Horton et al. Nov 2002 A1
20020166618 Wolf et al. Nov 2002 A1
20020175782 Trinh et al. Nov 2002 A1
20020183796 Connelly Dec 2002 A1
20020198569 Foster et al. Dec 2002 A1
20030036774 Maier et al. Feb 2003 A1
20030036776 Foster et al. Feb 2003 A1
20030045907 MacDonald Mar 2003 A1
20030053284 Stevenson et al. Mar 2003 A1
20030055457 MacDonald Mar 2003 A1
20030056820 MacDonald Mar 2003 A1
20030074029 Deno et al. Apr 2003 A1
20030081370 Haskell et al. May 2003 A1
20030083570 Cho et al. May 2003 A1
20030083723 Wilkinson et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030083728 Greatbatch et al. May 2003 A1
20030100925 Pape et al. May 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030111142 Horton et al. Jun 2003 A1
20030114897 Von Arx et al. Jun 2003 A1
20030114898 Von Arx et al. Jun 2003 A1
20030120197 Kaneko et al. Jun 2003 A1
20030130647 Gray et al. Jul 2003 A1
20030130700 Miller et al. Jul 2003 A1
20030130701 Miller Jul 2003 A1
20030130708 Von Arx et al. Jul 2003 A1
20030135114 Pacetti et al. Jul 2003 A1
20030135160 Gray et al. Jul 2003 A1
20030139096 Stevenson et al. Jul 2003 A1
20030140931 Zeijlemaker et al. Jul 2003 A1
20030144704 Terry et al. Jul 2003 A1
20030144705 Funke Jul 2003 A1
20030144706 Funke Jul 2003 A1
20030144716 Reinke et al. Jul 2003 A1
20030144717 Hagele Jul 2003 A1
20030144718 Zeijlemaker Jul 2003 A1
20030144719 Zeijlemaker Jul 2003 A1
20030144720 Villaseca et al. Jul 2003 A1
20030144721 Villaseca et al. Jul 2003 A1
20030149459 Von Arx et al. Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030176900 MacDonald Sep 2003 A1
20030179536 Stevenson et al. Sep 2003 A1
20030191505 Gryzwa et al. Oct 2003 A1
20030195570 Deal et al. Oct 2003 A1
20030199755 Halperin et al. Oct 2003 A1
20030204207 MacDonald et al. Oct 2003 A1
20030204215 Gunderson et al. Oct 2003 A1
20030204217 Greatbatch Oct 2003 A1
20030213604 Stevenson et al. Nov 2003 A1
20030213605 Brendel et al. Nov 2003 A1
20040005483 Lin Jan 2004 A1
20040015162 McGaffigan Jan 2004 A1
20040015197 Gunderson Jan 2004 A1
20040019273 Helfer et al. Jan 2004 A1
20040049237 Larson et al. Mar 2004 A1
20040088012 Kroll et al. May 2004 A1
20040093432 Luo et al. May 2004 A1
20040263174 Gray et al. Dec 2004 A1
20050070975 Zeijlemaker et al. Mar 2005 A1
20050113676 Weiner et al. May 2005 A1
20050113873 Weiner et al. May 2005 A1
20050113876 Weiner et al. May 2005 A1
20050197677 Stevenson Sep 2005 A1
20050222656 Wahlstrand et al. Oct 2005 A1
20050222657 Wahlstrand et al. Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen et al. Oct 2005 A1
20060025820 Phillips et al. Feb 2006 A1
20060030774 Gray et al. Feb 2006 A1
20060041294 Gray Feb 2006 A1
20060167496 Nelson et al. Jul 2006 A1
20060247747 Olsen et al. Nov 2006 A1
20060247748 Wahlstrand et al. Nov 2006 A1
20060271138 MacDonald Nov 2006 A1
20060293591 Wahlstrand et al. Dec 2006 A1
20070021814 Inman et al. Jan 2007 A1
20070179577 Marshall et al. Aug 2007 A1
20070179582 Marshall et al. Aug 2007 A1
20070191914 Stessman Aug 2007 A1
20070203523 Betzold Aug 2007 A1
20070238975 Zeijlemaker Oct 2007 A1
20070255332 Cabelka et al. Nov 2007 A1
20080033497 Bulkes et al. Feb 2008 A1
20080132985 Wedan et al. Jun 2008 A1
20080221638 Wedan et al. Sep 2008 A1
20090138058 Cooke et al. May 2009 A1
20090149906 Ameri et al. Jun 2009 A1
20090149909 Ameri Jun 2009 A1
20090204182 Ameri Aug 2009 A1
20090210025 Ameri Aug 2009 A1
20100087892 Stubbs et al. Apr 2010 A1
20100211123 Stubbs et al. Aug 2010 A1
Foreign Referenced Citations (53)
Number Date Country
0530006 Mar 1993 EP
0591334 Apr 1994 EP
0331959 Dec 1994 EP
0891786 Jan 1999 EP
0891207 Nov 1999 EP
0980105 Feb 2000 EP
0989623 Mar 2000 EP
0989624 Mar 2000 EP
1007132 Jun 2000 EP
1109180 Jun 2001 EP
1128764 Sep 2001 EP
0705621 Jan 2002 EP
1191556 Mar 2002 EP
1271579 Jan 2003 EP
0719570 Apr 2003 EP
1308971 May 2003 EP
1007140 Oct 2003 EP
1372782 Jan 2004 EP
0870517 Jun 2004 EP
1061849 Nov 2005 EP
1060762 Aug 2006 EP
0836413 Aug 2008 EP
WO9104069 Apr 1991 WO
WO9638200 Dec 1996 WO
WO9712645 Apr 1997 WO
WO0054953 Sep 2000 WO
WO0137286 May 2001 WO
WO0180940 Nov 2001 WO
WO0186774 Nov 2001 WO
WO02056761 Jul 2002 WO
WO02065895 Aug 2002 WO
WO02072004 Sep 2002 WO
WO02089665 Nov 2002 WO
WO02092161 Nov 2002 WO
WO03013199 Feb 2003 WO
WO03037399 May 2003 WO
WO03059445 Jul 2003 WO
WO03061755 Jul 2003 WO
WO03063952 Aug 2003 WO
WO03063954 Aug 2003 WO
WO03063955 Aug 2003 WO
WO03063956 Aug 2003 WO
WO03063958 Aug 2003 WO
WO03063962 Aug 2003 WO
WO03070098 Aug 2003 WO
WO03073449 Sep 2003 WO
WO03073450 Sep 2003 WO
WO03086538 Oct 2003 WO
WO03090846 Nov 2003 WO
WO03090854 Nov 2003 WO
WO03095022 Nov 2003 WO
WO03063946 Apr 2005 WO
WO2006124481 Nov 2006 WO
Non-Patent Literature Citations (11)
Entry
Dempsey Mary F. et al., “Investigation of the Factors Responsible for Burns During MRI”, Journal of Magnetic Resonance Imaging 2001:13:627-631.
File History for U.S. Appl. No. 11/015,807, filed Dec. 17, 2004.
International Search Report and Written Opinion issued in PCT/US2009/059093, mailed Dec. 29, 2009.
International Search Report and Written Opinion issued in PCT/US2009/068314, mailed Mar. 25, 2009, 14 pages.
Kerr, Martha, “Shock Rate Cut 70% With ICDs Programmed to First Deliver Antitachycardia Pacing: Results of the PainFREE Rx II Trial,” Medscape CRM News, May 21, 2003.
Luechinger, Roger et al., “In vivo heating of pacemaker leads during magnetic resonance imaging”, European Heart Journal 2005;26:376-383.
Schueler, et al., “MRI Compatibility and Visibility Assessment of Implantable Medical Devices”, Journal of Magnetic Resonance Imaging, 9:596-603 (1999).
Shellock FG, “Reference manual for magnetic resonance safety, implants, and devices”, pp. 136-139, 2008 ed. Los Angeles; Biomedical Research Publishing Group; 2008.
Shellock, Frank G. et al., “Cardiovascular catheters and accessories: ex vivo testing of ferromagnetism, heating, and artifacts associated with MRI”, Journal of Magnetic Resonance Imaging, Nov./Dec. 1998; 8:1338-1342.
Sweeney, Michael O. et al., Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock Therapies (PainFREE Rx II) Trial, American Heart Association, 2005.
Wilkoff, Bruce L. et al., “A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators Results From the Prospective Randomized Multicenter EMPIRIC Trial,” Journal of the American College of Cardiology vol. 48, No. 2, 2006. doi:10.1016/j.jacc.2006.03.037.
Related Publications (1)
Number Date Country
20110270338 A1 Nov 2011 US
Divisions (1)
Number Date Country
Parent 11015807 Dec 2004 US
Child 13178571 US